Trial Profile
Mechanisms Underlying Asthma Exacerbations Prevented and Persistent With Immune-Based Therapy: A Systems Approach Phase 2 (ICAC-30)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 23 Jun 2022
Price :
$35
*
At a glance
- Drugs Mepolizumab (Primary)
- Indications Asthma
- Focus Therapeutic Use
- Acronyms MUPPITS-2
- 27 Apr 2021 Status changed from active, no longer recruiting to completed.
- 22 Jan 2021 Planned End Date changed from 1 Apr 2021 to 1 May 2021.
- 22 Jan 2021 Planned primary completion date changed from 1 Apr 2021 to 1 May 2021.